Systemic Treatment Drugs and Regimens
This chapter discusses chemotherapy regimens and targeted options for breast cancer treatment. Dose-limiting toxicities for targeted therapies are often markedly different from those of classic cytotoxic chemotherapy agents. The profit/loss ratio of treatment should be adequately evaluated, and toxicity may not cause life-threatening conditions. However, decreasing the dosage under the therapeutic range may cause under-dosing in patients, which may compromise cancer outcomes. It is very important to know how to adjust the dose according to toxicity without changing the effectiveness of the drug.
- 1.Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. 2017, National Institutes of Health, National Cancer Institute.Google Scholar
- 3.Child CG III, Turcotte JG. Surgery and portal hypertension. In: Child III CG, editor. The liver and portal hypertension. Philadelphia: W. B. Saunders; 1964. p. 50.Google Scholar
- 4.Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016;18(1):67. https://doi.org/10.1186/s13058-016-0721-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy155.
- 9.Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–77.CrossRefGoogle Scholar
- 12.Tykerb (lapatinib) [prescribing information]; 2017. East Hanover, NJ: Novartis Pharmaceuticals Corporation.Google Scholar